Form 4 for HUMA Humacyte, Inc.
Accepted 2022-12-19 00:00:00 ET · period of report 2022-12-15 · accession 0001818382-22-000223 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-19 | 2022-12-15 | HUMA | Niklason Laura E | Pres, CEO, Dir, 10% | P - Purchase | $2.54 | +10.0K | 1.17M | +0.9% | +$25.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-15 | P | A | 10,000 | $2.54 | 1,170,240 | D | — | — | (F1) This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 1,522,500 shares of the Issuer's common stock on September 15, 2022, at a per share price of $4.00. The Reporting Person has paid the Issuer $14,604.95, representing the full amount of profit realized in connection with this purchase. (F2) The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.53 to $2.55. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |